Abstract
Novel treatments have significantly increased the rates of complete response (CR) in patients with multiple myeloma (MM), however most of them will eventually relapse. The presence of minimal residual disease (MRD) has emerged as a valuable biomarker as it discriminates patients with a higher risk of progression despite the achievement of CR. Previous studies have highlighted the prognostic value of MRD negativity at the time of CR after frontline therapy; there is limited data on the impact of MRD in patients achieving long-term CR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
